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Abstract
Background—High-throughput profiling of circulating metabolites may improve cardiovascular 
risk prediction over established risk factors.
Methods and Results—We applied quantitative NMR metabolomics to identify biomarkers for 
incident cardiovascular disease during long-term follow-up. Biomarker discovery was conducted 
in the FINRISK study (n=7256; 800 events). Replication and incremental risk prediction was 
assessed in the SABRE study (n=2622; 573 events) and British Women’s Health and Heart Study 
(n=3563; 368 events). In targeted analyses of 68 lipids and metabolites, 33 measures were 
associated with incident cardiovascular events at P<0.0007 after adjusting for age, sex, blood 
pressure, smoking, diabetes and medication. When further adjusting for routine lipids, four 
metabolites were associated with future cardiovascular events in meta-analyses: higher serum 
phenylalanine (hazard ratio per standard deviation: 1.18 [95%CI 1.12–1.24]; P=4×10−10) and 
monounsaturated fatty acid levels (1.17 [1.11–1.24]; P=1×10−8) were associated with increased 
cardiovascular risk, while higher omega-6 fatty acids (0.89 [0.84–0.94]; P=6×10−5) and 
docosahexaenoic acid levels (0.90 [0.86–0.95]; P=5×10−5) were associated with lower risk. A risk 
score incorporating these four biomarkers was derived in FINRISK. Risk prediction estimates 
were more accurate in the two validation cohorts (relative integrated discrimination improvement 
8.8% and 4.3%), albeit discrimination was not enhanced. Risk classification was particularly 
improved for persons in the 5–10% risk range (net reclassification 27.1% and 15.5%). Biomarker 
associations were further corroborated with mass spectrometry in FINRISK (n=671) and the 
Framingham Offspring Study (n=2289).
Conclusions—Metabolite profiling in large prospective cohorts identified phenylalanine, 
monounsaturated and polyunsaturated fatty acids as biomarkers for cardiovascular risk. This study 
substantiates the value of high-throughput metabolomics for biomarker discovery and improved 
risk assessment.
Keywords
biomarkers; metabolomics; risk prediction; amino acids; fatty acids
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. 
Preventive cardiovascular risk assessment relies on established risk factors, including 
dyslipidemia, hypertension and diabetes; however, the first CVD events often originate from 
people classified as being at low or intermediate risk based on current risk algorithms.1–4 
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Detailed profiling of metabolic status, termed metabolite profiling or metabolomics, can 
provide insights into the molecular mechanisms underlying atherosclerosis.5–9 The 
quantification of large numbers of circulating metabolites across multiple pathways may 
also identify metabolic changes prior to the onset of overt disease, and hereby potentially 
lead to earlier and more accurate identification of individuals at high cardiovascular 
risk.10–12
Metabolite profiling has successfully been applied to identify biomarkers for the 
development of type 2 diabetes;13–17 however, few metabolite biomarkers have been 
consistently associated with future cardiovascular events across multiple studies.6,10–12,18 
Technological improvements in sample throughput now allow for metabolite profiling of 
extensive epidemiological cohorts, rather than case-control settings, to enhance biomarker 
discovery and replication.8–10,16–22 Serum nuclear magnetic resonance (NMR) 
metabolomics enables fast, inexpensive and reproducible quantification of circulating lipids 
and abundant metabolites.8,18,19,23–25 Here, we used a high-throughput NMR platform8 for 
metabolite profiling in three large population-based cohorts with the aim of identifying 
circulating biomarkers for cardiovascular risk during long-term follow-up. First, 68 lipid and 
metabolite measures from multiple pathways were tested for association with incident CVD. 
This hypothesis-generating approach was taken to discover novel biomarkers, and hereby 
gain information on disease mechanisms. The ability to improve cardiovascular risk 
assessment, beyond that achieved by established risk factors, was examined by a risk score 
including metabolite biomarkers derived in the discovery study and tested in the two 
validation cohorts.
Analytical confirmation of the identified biomarkers was provided by complementary mass 
spectrometry and gas chromatography. To examine the coherence across metabolomics 
methodologies, the NMR-based biomarker associations with CVD were further compared 
with those obtained from mass spectrometry in the discovery study as well as independently 
in the Framingham Offspring Study.
METHODS
Study populations
An overview of the study design is shown in Figure 1. This observational study examined 
metabolite associations with incident cardiovascular events in the population-based 
FINRISK study as discovery cohort. Metabolite biomarker candidates were replicated in two 
additional population-based cohorts. All participants provided written informed consent, and 
study protocols were approved by the local ethical committees. The main endpoint was the 
first incidence of a major cardiovascular event during follow-up, which includes fatal or 
nonfatal occurrence of myocardial infarction, ischemic stroke, cardiac revascularization 
(coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty), or 
unstable angina.26 Individuals with prevalent CVD at enrolment were omitted from 
analyses.
The FINRISK 1997 study is a general population survey conducted to monitor the health of 
the Finnish population among persons aged 25–74 at recruitment.22,26,27 In total, 8444 
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individuals were recruited from five study areas across Finland. Participants completed 
questionnaires on smoking status, alcohol usage, and medication. Median fasting time was 
5h (interquartile range 4–6h). Serum total cholesterol, high-density lipoprotein (HDL) 
cholesterol, and triglycerides were measured with enzymatic methods. Metabolite profiling 
by high-throughput NMR was measured during 2012 for 7602 individuals with serum 
samples collected in 1997 available.22 Pregnant women and persons missing risk factor 
information (n=83), and individuals with prevalent CVD (n=263) were excluded, leaving 
7256 individuals for statistical analyses. Tracking of CVD during follow-up (1997 through 
December 2011) was enabled by ICD-10 diagnosis codes from the Finnish National 
Hospital Discharge Register and Causes-of-Death Register. These registers cover all 
cardiovascular events that have led either to hospitalization or death in Finland. The 
cardiovascular diagnoses in these registers have been validated.28
Replication of biomarker associations with CVD and improvements in risk prediction were 
examined in two population-based studies from the UK: fasting serum samples from the 
Southall and Brent Revisited study (SABRE, n=2622)29 and the British Women’s Heart and 
Health Study (BWHHS, n=3563)30 were profiled by the same NMR metabolomics platform 
as used in FINRISK. Detailed information on the study populations is provided in the 
expanded methods online.
Metabolite quantification
A high-throughput NMR metabolomics platform8 was used for the quantification of 68 lipid 
and abundant metabolite measures from baseline serum samples of the FINRISK, SABRE, 
and BWHHS cohorts. All metabolites were measured in a single experimental setup, which 
allows for the simultaneous quantification of both routine lipids, total lipid concentrations of 
14 lipoprotein subclasses, fatty acid composition such as monounsaturated (MUFA) and 
polyunsaturated fatty acids (PUFA), various glycolysis precursors, ketone bodies and amino 
acids in absolute concentration units (Supplemental Table 1).8 The targeted metabolite 
profiling therefore includes both known metabolic risk factors and metabolites from multiple 
physiological pathways, which have not previously been examined in relation to CVD risk 
in large population studies. The 68 metabolite measures were assessed for association with 
incident CVD events using a hypothesis-generating biomarker discovery approach with 
subsequent replication in two independent cohorts. Spearman’s correlations of the 
metabolites are shown in Supplemental Figure 1. The NMR metabolomics platform has 
previously been used in various epidemiological studies9,10,16,17,20–22,31,32, details of the 
experimentation have been described9,24, and the method has recently been reviewed.8,19
A subset of 679 serum samples from the FINRISK study were additionally profiled with 
liquid-chromatography mass spectrometry (LC-MS) using the Metabolon platform33 in a 
case-cohort design for comparison of biomarker associations with incident CVD (expanded 
methods online). The biomarker associations were further compared with those obtained by 
LC-MS-based profiling of the Framingham Offspring Study (fifth examination cycle, 
n=2289 fasting plasma samples), as described in detail previously.13,14 Since several fatty 
acid biomarkers were not measured by LC-MS, the quantification was analytically 
confirmed by comparing NMR and gas chromatography in the Cardiovascular Risk in 
Würtz et al. Page 4
Circulation. Author manuscript; available in PMC 2016 March 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Young Finns Study (YFS, n=2193 fasting serum samples).34 Metabolite profiling data 
collected at two-time points in YFS9 was further used to examine associations of dietary 
intake with the circulating biomarkers, and tracking of concentrations within the same 
individuals over 6 years.
Statistical analyses
All metabolite concentrations were first log-transformed prior to analyses to obtain 
approximately normal distributions. The metabolite measures were subsequently scaled to 
standard deviation (SD) units separately for each cohort. Associations with incident CVD 
were analyzed separately for each metabolite using Cox proportional hazards regression 
models. In the FINRISK discovery study, metabolite associations were first adjusted for age 
(as time scale), sex, systolic blood pressure, smoking, prevalent diabetes, antihypertensive 
treatment, lipid treatment, and geographical region, and subsequently tested with additional 
adjustment for routine lipid measures (total cholesterol and HDL cholesterol). Metabolites 
associated with CVD at P<0.05 when adjusting for routine lipids were then analyzed in the 
two replication cohorts with full adjustment. Analyses in SABRE were further adjusted for 
ethnicity. Results from individual cohorts were combined using inverse variance-weighted 
fixed-effect meta-analysis. Metabolites associated with incident CVD at P<0.0007 in meta-
analyses were denoted significant biomarkers (Bonferroni correction of P<0.05 accounting 
for 68 independent tests). Sensitivity analyses were conducted in the FINRISK study with 
additional exclusion criteria and covariate adjustment. Metabolites that were nominally 
significant in the meta-analysis (P<0.05) were also tested for association with cardiovascular 
mortality. Since phenylalanine did not meet the proportional hazards assumptions by the 
scaled Schoenfeld’s residuals test in the FINRISK study, the association was tested for 
interaction with age. Phenylalanine was further examined for association with death from 
coronary heart disease and stroke in meta-analyses.
The potential to improve cardiovascular risk prediction was evaluated by risk scores derived 
based on established factors with and without the significant metabolite biomarkers in the 
models. A multi-biomarker risk score was derived in the FINRISK discovery cohort: all 
combinations of the five significant biomarkers were tested, with established risk factors 
always included in the model. The model giving rise to the best fit based on the Akaike 
Information Criterion was selected. The logarithm of the hazard ratios (HRs) in the 
multivariable model were used as the linear predictor for the biomarker risk score. A 
reference risk score was also derived in the FINRISK study by using only the conventional 
risk factors to define the linear predictor. Due to differences in hazard depending on age and 
geographical regions, the baseline hazard term was derived within each validation cohort. 
The predictive utility of the biomarker risk score was examined in the two validation cohorts 
in terms of risk discrimination and reclassification. Prediction estimates were calculated as 
15-year absolute risk in SABRE (matching the FINRISK follow-up) and as 12-year absolute 
risk in BWHHS. Discrimination was assessed by the correlated censored C-statistic 
approach using jackknife estimation accounting for censoring35 and integrated 
discrimination improvement (IDI). IDI is the difference of mean predicted probabilities 
(absolute risk estimates) between the biomarker score and the reference score for events 
minus the corresponding difference in predicted probabilities for non-events.36,37 IDI thus 
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denotes the average increase in absolute risk estimates by the biomarker risk score for 
individuals who experienced a CVD event plus the average decrease in absolute risk 
estimates for those who did not have a CVD event. Since the absolute risk estimates are 
generally low in the study populations, the relative IDI offers a more intuitive understanding 
of the average improvement in risk prediction accuracy achieved by the biomarker model.36 
Net reclassification improvement (NRI) was examined to determine the extent to which the 
biomarker risk score reassigned individuals to risk categories that more correctly reflected 
whether or not they experienced a CVD event during follow-up. NRI was assessed in two 
risk category ranges: 1) only for individuals in the intermediate risk range of 5–10% based 
on the reference score (clinical NRI)3,4,38, and 2) for the whole study population using the 
risk categories <5%, 5–10% and >10% (categorical NRI).36 In addition, we assessed the 
continuous NRI, which deems any change in predicted risk in the correct direction as 
appropriate without dependency of risk categories.37 All reclassification metrics were 
examined separately for events and non-events, and net reclassification denotes the 
unweighted sum of the two. Model calibration within risk deciles was assessed by Hosmer-
Lemeshow goodness-of-fit test.2
Assessment of the consistency of biomarker associations between NMR and mass 
spectrometry and analytical confirmation of the biomarker quantification is described in the 
expanded methods online. Details of the biomarker associations with dietary data, and 
tracking of metabolite concentrations over time can also be found in expanded methods 
online.
RESULTS
The discovery study included 7256 individuals from the FINRISK general-population 
cohort, free of CVD at baseline. During a follow-up of 15-years, 800 persons experienced an 
incident cardiovascular event. Metabolite biomarker candidates for CVD were replicated in 
the two UK-based population-based cohorts: 2622 individuals from SABRE and 3563 
women from BWHHS, with a total of 941 incident cardiovascular events during 12–23 year 
follow-up. Baseline characteristics and cardiovascular event numbers are summarized in 
Table 1.
Metabolite Associations With Incident Cardiovascular Events
To generate hypotheses on the roles of the metabolite measures in cardiovascular 
pathophysiology, we first examined each metabolite for association with incident CVD in 
the FINRISK discovery study with adjustment only for established non-laboratory risk 
factors: age as time-scale, sex, systolic blood pressure, smoking, prevalent diabetes, 
geographical region, lipid medication, and antihypertensive treatment.2–4 Associations of the 
68 lipid and metabolite measures with incident cardiovascular events are illustrated in 
Figure 2. HRs are scaled to 1-SD increments in log-transformed metabolite concentrations to 
facilitate comparison across metabolites. Overall, 33 metabolite measures were associated 
with future cardiovascular events at P<0.0007 (Bonferroni correction for 68 tests). 
Prominent associations with increased CVD risk were observed for higher circulating 
concentrations of aromatic amino acids, glycolysis metabolites, MUFA relative to total fatty 
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acids (MUFA%), glycoprotein acetyls, as well as the lipid concentrations within medium 
and small very-low-density lipoproteins, intermediate-density lipoprotein and low-density 
lipoproteins. The strongest inverse associations with cardiovascular risk were found for 
lower concentrations of lipids within large HDL particles and for HDL cholesterol. 
Noticeably inverse associations were also observed for ketone bodies as well as ratios of 
omega-3 and omega-6, relative to total fatty acids. The metabolite associations were broadly 
consistent between men and women (Supplemental Figure 2).
To discover metabolite biomarkers for incident CVD independent of routine lipids, analyses 
were further adjusted for total- and HDL-cholesterol. In the FINRISK discovery study, 19 
metabolite measures were associated with cardiovascular events at P<0.05 when adjusting 
for routine lipids in the model (Supplemental Figure 3). These biomarker candidates were 
then further analyzed in the two replication cohorts. In meta-analyses, five metabolite 
measures were significantly associated with cardiovascular events (P<0.0007; Figure 3). 
Higher phenylalanine and MUFA% levels were associated with increased cardiovascular 
event risk. Higher concentrations of omega-6 fatty acids, total concentrations of PUFA, and 
docosahexaenoic acid (DHA; an omega-3 fatty acid) were associated with lower risk. The 
biomarker associations with CVD in absolute concentration units (without log-transform and 
SD-scaling) as well as for upper vs. lower quartiles are listed in Supplemental Table 2. The 
biomarker associations remained similar with additional subject exclusion criteria and 
adjustment factors (Supplemental Figure 4). In particular, associations were stronger with 
further adjustment for serum triglycerides. The magnitudes of the biomarker associations 
were comparable to those of routine lipid measures (Supplemental Figure 5). Metabolite 
measures displaying nominal association with incident CVD are listed in Supplemental 
Figure 6. The metabolite associations were similar or stronger with cardiovascular mortality 
as outcome (Supplemental Figure 7).
While the fatty acid measures displayed coherent associations with incident CVD in each 
cohort, some study heterogeneity was evident in the case of phenylalanine (meta-analysis 
heterogeneity statistic I2=63%, P=0.07; Figure 3). A potential reason may be the interaction 
of phenylalanine with age at end of follow-up (P=0.001 in FINRISK), indicating stronger 
associations of phenylalanine with cardiovascular events at younger age (Figure 4). This 
interaction, with approximately 1% weaker association per year, was consistent in SABRE 
but did not replicate in the older population, with narrower age-range (60–79 years at 
baseline) from BWHHS (Supplemental Figure 8). While phenylalanine was only weakly 
associated with incident cardiovascular events in BWHHS, the amino acid was consistently 
associated with death from coronary heart disease across all three cohorts (Figure 5). In 
contrast, no association was observed for phenylalanine with death from stroke.
Cardiovascular risk score validation and reclassification
A risk prediction score including metabolite biomarkers was derived in the FINRISK 
discovery study. The best model fit was obtained by incorporating four out of the five 
biomarkers (Figure 3) in the score along with established risk factors: phenylalanine, 
MUFA(%), omega-6 fatty acids, and DHA. Coefficients for calculating the risk prediction 
scores with and without these biomarkers are listed in Supplemental Table 3. The potential 
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of the biomarker score to improve risk discrimination and reclassification was tested in the 
SABRE and BWHHS cohorts (Table 2). Although discrimination assessed using the C-
statistic was not enhanced, the risk prediction estimates were on average more accurate in 
the two validation cohorts, both for those who had a CVD event during follow-up (mean 
improvement in risk prediction accuracy or relative IDI 4.5% for SABRE and 3.2% for 
BWHHS) and for those who did not (relative IDI 4.4% for SABRE and 1.1% for BWHHS). 
The model calibration was modest (Supplemental Figure 9), in particular for the older 
women from BWWHS, where both the reference and biomarker risk scores provided 
mediocre discrimination. The continuous risk reclassification was improved by the 
biomarker risk score among individuals who did not experience a cardiovascular event 
(26.8% for SABRE and 15.6% for BWHHS). The net categorical NRI for the whole study 
population was 7.6% for SABRE and 5.3% for BWHHS. Most notably, for persons 
classified in the intermediate risk range (5–10%) based on the reference risk score there was 
a substantial up-classification by the biomarker score to >10% risk among individuals who 
actually developed CVD (clinical NRI among events 20.5% for SABRE and 9.8% for 
BWHHS). Similarly, there was a significant down-classification by the biomarker score to 
<5% for those who remained free of CVD during follow-up (clinical NRI among non-events 
6.6% for SABRE and 5.7% for BWHHS). Reclassification tables for the intermediate risk 
range are shown in Supplemental Table 4.
Cross-platform biomarker confirmation
To verify the biomarker associations across metabolomics methods, we tested metabolites 
that were overlapping between the NMR platform and LC-MS for association with incident 
CVD. In the Framingham Offspring Study (n=2289, 466 events during 12-year follow-up), 
the biomarker associations were consistent with those obtained from NMR, albeit 
phenylalanine was weaker (Figure 6). The biomarker associations were also consistent 
between NMR and LC-MS when compared within the same set of individuals in a case-
cohort subset of the FINRISK study (n=679, 305 incident events; Figure 6). Comparisons of 
biomarker associations across metabolomics platforms with adjustment for age and sex only 
are shown in Supplemental Figure 10. The correspondence between phenylalanine 
(Pearson’s correlation r=0.62) and DHA (r=0.77) quantified by NMR and LC-MS is shown 
in Supplemental Figure 11. MUFA ratio, relative to total fatty acids, and omega-6 fatty acids 
were not measured by mass spectrometry; quantification of these biomarkers was instead 
confirmed by comparison with gas chromatography in 2193 participants from the YFS 
cohort (Supplemental Figure 12). The fatty acid quantification was highly consistent 
between methods: r=0.92 for MUFA (%), r=0.97 for omega-6 fatty acids and r=0.95 for 
DHA.
Biomarker tracking and dietary associations
The metabolite biomarker levels were consistent over 6-year follow in YFS (tracking 
correlations 0.41–0.47) and only slightly weaker over 20-year follow-up in the SABRE 
study (Supplemental Table 5). We further examined associations of dietary intake with the 
circulating biomarker concentrations at two time-points in YFS. Dietary DHA was robustly 
associated with serum DHA levels (P<0.0001 at both time-points), whereas dietary measures 
of phenylalanine, omega-6, and MUFA% were not strongly associated with the 
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corresponding circulating levels (Supplemental Figure 13). Circulating phenylalanine levels 
were not associated with aspartame in the 652 individuals from FINRISK with data 
available on this artificial sweetener (Spearman correlation −0.06, P=0.14).
DISCUSSION
Using high-throughput metabolite profiling in three general-population studies, we 
identified phenylalanine and three measures of fatty acids as independent biomarkers for 
future cardiovascular events. The circulating metabolites were as strongly predictive of 
cardiovascular risk as the conventional lipid risk factors, and were markers of CVD onset 
during more than a decade follow-up. The biomarker associations replicated in independent 
cohorts with varying baseline characteristics including age and ethnicity, and were 
consistent across different metabolite profiling platforms. Whereas higher circulating levels 
of DHA and omega-6 fatty acids have been linked with lower CVD event risk in some 
studies,39–41 the blood levels of MUFA and phenylalanine have not previously been 
associated with higher risk for future CVD in large epidemiological studies. These results 
demonstrate the power of detailed metabolite profiling for biomarker discovery in large 
prospective cohorts, which can yield improved molecular understanding of disease 
mechanisms. In combination, the four biomarkers indicated improved cardiovascular risk 
assessment for people in the intermediate risk range, where clinical decision making remains 
ambiguous.
Phenylalanine is an essential aromatic amino acid, and precursor for tyrosine and dopamine-
related neurotransmitters. The mechanisms by which blood levels of phenylalanine relate to 
cardiovascular risk remain unknown. Phenylalanine has been associated with insulin 
resistance and the risk for diabetes;13–16 however, the association with CVD remained 
similar after adjustment for glucose and insulin. A small case-control study using LC-MS 
suggested an amino acid score including phenylalanine to be associated with CVD.42 
Although phenylalanine alone was not statistically significant in that study, the HR (1.25; 
P=0.11) matched the magnitude observed in the present study. The ratio of phenylalanine to 
tyrosine has been suggested as a proxy of phenylalanine hydroxylase activity;43 however, 
this ratio was not associated with CVD event risk in the present study (HR=1.03; P=0.47). 
Phenylalanine was more strongly associated with CVD before the age of 60. This amino 
acid therefore represents a promising biomarker for early identification of cardiovascular 
risk.
Dietary recommendations support MUFA intake replacing saturated fatty acid to lower 
cardiovascular risk.44 In this study, high blood levels of MUFAs, relative to total fatty acids, 
were associated with higher cardiovascular risk. Similar results have been found for the risk 
of diabetes.17 However, circulating MUFA concentrations do not directly reflect dietary 
intake, since MUFAs constitute the major fatty acids stored in adipose tissue and can be 
synthesized de novo. A potential explanation for the positive association with CVD may be 
that the MUFA levels originate from desaturation of dietary saturated fatty acids.17,45 As 
such, MUFA% could potentially act as a blood biomarker reflecting long-term dietary 
quality.
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The role of PUFAs in CVD pathogenesis remains controversial.39–41,46–49 Intervention trials 
do not suggest risk reduction by omega-3 supplementation.46,47 Trials on omega-6 fatty acid 
consumption are less clear, as most studies evaluate effects of replacing saturated fatty 
acids.48,49 We observed consistent associations of higher blood levels of both DHA and 
omega-6 fatty acids with lower CVD risk, in agreement with some prospective studies on 
circulating PUFAs.39–41 These findings contrast results on the risk for incident diabetes, 
where only omega-6 fatty acids display inverse associations.17 Circulating PUFAs might 
serve as more reliable markers of therapeutic target and cardiovascular risk than 
conventional dietary assssments.10,39–41 Regardless of the therapeutic benefit, DHA and 
omega-6 fatty acid quantification could potentially augment risk assessment on top of 
established risk factors.
Individual biomarkers rarely improve risk prediction.1 The biomarkers identified here were 
quantified by a single analytical platform, which also features measurement of routine lipid 
risk factors.8,9,20,24,31,32 The combination of four biomarkers yielded improvements in risk 
prediction accuracy when evaluated in two independent cohorts. The average improvement 
in risk prediction accuracy (relative IDI) was ~4.5% in SABRE for both individuals who 
developed CVD and those who did not, and 1–3% in BWHHS. This modest improvement 
might relate to differences in age and gender distributions, population sampling, ethnicity, 
and geographical region between derivation and validation cohorts. The poor model 
calibration and lower reclassification rates in BWHHS may potentially be explained by the 
female-only composition as well as the higher baseline age of this study cohort. Novel 
biomarkers for risk prediction are primarily needed for persons in the intermediate risk 
range, for whom treatment decisions are most challenging.1–4 The four biomarkers proved 
particularly helpful in correctly reclassifying individuals in the 5–10% risk grey zone (net 
27% and 15% in the two validation cohorts). Although there are no widely accepted 
definitions of intermediate risk for the composite CVD endpoint studied here, also the 
continuous reclassification metrics were improved in both validation studies. Nonetheless, 
additional investigations should further evaluate the clinical utility of these biomarkers. In 
particular, metabolite profiling in clinical trials could inform on the feasibility of using the 
biomarkers to improve cardiovascular risk assessment. The throughput of the metabolomics 
platform employed now allows for profiling all samples collected in even the largest CVD 
prevention trials.8 This would elucidate the role of detailed metabolite profiling in high-risk 
individuals and patients with prevalent disease, and address the value for risk assessment 
among patients already on statin medication.
Our study has several strengths, including the large number of individuals studied, 
biomarker replication, assessment of risk prediction in independent cohorts, and 
confirmation of biomarker associations across metabolomics methodologies. Some 
limitations should also be considered. First, the metabolite coverage by NMR is limited 
compared to that afforded by mass spectrometry, which might further improve risk 
prediction.5,12 Second, blood sample collections were done before the widespread use of 
lipid-lowering medication and the benefit of modern preventive treatment based on risk 
classification by the highlighted biomarkers remains uncertain.
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Conclusion
Using NMR metabolomics profiling of 13441 individuals with long-term follow-up, we 
have identified phenylalanine and MUFA as novel biomarkers of higher CVD event risk, 
and corroborated omega-6 fatty acids and DHA as biomarkers of lower CVD risk. The 
combination of the four independent biomarkers indicated improved prediction of 
cardiovascular risk for persons classified with intermediate risk based on established risk 
factors. Further studies are needed to elucidate the biological mechanisms underlying the 
associations with CVD, and to clarify the clinical utility of these biomarkers to guide 
cardiovascular risk assessment. Overall, our investigation underscores the value of high-
throughput metabolite profiling in discovery of new and emerging biomarkers for CVD risk 
and their potentially cost-effective use for cardiovascular prevention.
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Figure 1. 
Overview of the study design and statistical analyses conducted.
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Figure 2. 
Metabolite associations with future cardiovascular events. Hazard ratios of 68 metabolite 
measures with incident cardiovascular disease during 15-year follow-up in the FINRISK 
study (n=7256, 800 events). Hazard ratios are per 1-SD log-transformed metabolite 
concentration and adjusted for age, sex, blood pressure, smoking, diabetes, geographical 
region, and cardiovascular medication. Errorbars denote 95% confidence intervals.
★: P<0.0007 (multiple testing correction).
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Figure 3. 
Meta-analysis of metabolite biomarkers for future cardiovascular events. Hazard ratios of 
biomarkers with incident cardiovascular events in three population-based studies and meta-
analysis (n=13441; 1741 events during 12–23 years follow-up). Analyses are adjusted for 
age, sex, blood pressure, smoking, diabetes, geographical region, cardiovascular medication 
as well as total and HDL cholesterol. Hazard ratios are per 1-SD log-transformed metabolite 
concentration and errorbars denote 95% confidence intervals. I2 indicates heterogeneity of 
meta-analysis. Metabolites associated with cardiovascular events at P<0.0007 (multiple 
testing correction) are shown here; associations with P<0.05 are listed in Supplemental 
Figure 6. The four biomarkers highlighted in bold are independent of each other and were 
included in the risk prediction score.
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Figure 4. 
Phenylalanine interaction with age. Hazard ratios of phenylalanine with incident 
cardiovascular disease in different baseline age groups for the FINRISK study. Analyses 
were adjusted for age, sex, blood pressure, smoking, diabetes, geographical region, 
cardiovascular medication as well as total and HDL cholesterol. Hazard ratios are per 1-SD 
higher log-transformed phenylalanine concentration (approximately corresponding to 14 
μmol/L). Errorbars denote 95% confidence intervals. The dashed line denotes the hazard 
ratio for the full age range. The continuous interaction of phenylalanine with age is shown 
for all three cohorts in Supplemental Figure 8.
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Figure 5. 
Phenylalanine associations with vascular mortality. Hazard ratios of phenylalanine with 
death from cardiovascular disease, coronary heart disease and stroke in the three cohorts and 
meta-analysis (n=13815). Analyses were adjusted for age, sex, blood pressure, smoking, 
diabetes, geographical region, cardiovascular medication as well as total and HDL 
cholesterol. Hazard ratios are per 1-SD higher log-transformed phenylalanine concentration 
(approximately corresponding to 14 μmol/L). Errorbars denote 95% confidence intervals. 
The numbers of coronary and stroke deaths sum to a slightly higher number than the 
cardiovascular deaths, since we have considered all causes of death written in the death 
certificate.
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Figure 6. 
Consistency between NMR and LC-MS for biomarker associations with incident 
cardiovascular disease. Metabolites overlapping between metabolomics platforms and 
nominally associated with incident CVD in the present study (P<0.05, Supplemental Figure 
6) are shown. Left panel: Biomarker associations with CVD risk observed in the present 
study based on NMR (white diamonds) compared with those obtained in the Framingham 
Offspring Study based on LC-MS (red squares; n=2289, 466 events). Right panel: 
Biomarker associations with CVD risk in a case-cohort subset of the FINRISK study 
(n=679, 305 events) profiled both by NMR (black circles) and LC-MS (red circles). Hazard 
ratios are per 1-SD higher log-transformed metabolite concentration. Errorbars denote 95% 
confidence intervals. All associations were adjusted for age, sex, blood pressure, smoking, 
diabetes status, geographical region, cardiovascular medication as well as total and HDL 
cholesterol. LC-MS-based associations were further adjusted for batch. The corresponding 
age- and sex-adjusted biomarker associations are shown in Supplemental Figure 10. 
*Associations of omega-6 fatty acids were compared with lysophosphatidylcholine- and 
cholesterolester-linoleic acid in the Framingham Offspring Study, and with total linoleic 
acid in the FINRISK subset. † Associations of DHA were compared with 
lysophosphatidylcholine- and cholesterolester- DHA in the Framingham Offspring Study. ¶ 
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DHA ratio was scaled to the total fatty acid concentration quantified by NMR for both 
platforms. The DHA ratio was not measured in the Framingham Offspring Study.
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Table 1
Baseline characteristics of the study populations.
Clinical characteristics FINRISK 1997 study(n=7256)
Southall and Brent REvisted study 
(SABRE)
(n=2622)
British Women’s Heart and 
Health Study (BWHHS)
(n=3563)
Women (%) 3678 (51%) 386 (21%) 3563 (100%)
Location 6 regions in Finland London, United Kingdom 23 British towns
Age (years) 48±13 52±7 69±5
Body mass index (kg/m2) 26.6±4.5 26.1±3.7 27.5±4.9
Systolic blood pressure (mmHg) 136±20 124±18 147±25
Total cholesterol (mmol/L) 5.5±1.1 6.0±1.1 6.7±1.2
HDL cholesterol (mmol/L) 1.4±0.4 1.3±0.4 1.7±0.5
Triglycerides (mmol/L) 1.5±1.0 1.8±1.2 1.8±1.0
Lipid-lowering medication (%) 185 (2.6%) 5 (0.4%) 249 (7%)
Anti-hypertensive medication (%) 908 (13%) 294 (11%) 1033 (29%)
Current smoking (%) 1736 (24%) 592 (23%) 392 (11%)
Diabetes prevalence (%) 393 (5.4%) 314 (12%) 356 (10%)
Follow-up time (years, range) 15 20–23 11–13
Incident cardiovascular events 800 573 368
Data are number (%) or mean±SD when appropriate. HDL indicates high-density lipoprotein.
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